Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anzurstobart, a fully human monoclonal anti-SIRPα antibody, is characterized by high-affinity binding and inhibition of the CD47-SIRPα interaction, which is known to suppress macrophage activity. Anzurstobart enhances macrophage-mediated phagocytosis of diffuse large B-cell lymphoma (DLBCL) cell lines in co-culture with Rituximab, and it shows considerable promise in both solid and hematologic malignancy research, positioning it as a potential candidate for immuno-oncology applications.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $198 | In Stock | |
5 mg | $619 | In Stock | |
10 mg | $993 | In Stock | |
25 mg | $1,470 | In Stock | |
50 mg | $1,980 | In Stock |
Description | Anzurstobart, a fully human monoclonal anti-SIRPα antibody, is characterized by high-affinity binding and inhibition of the CD47-SIRPα interaction, which is known to suppress macrophage activity. Anzurstobart enhances macrophage-mediated phagocytosis of diffuse large B-cell lymphoma (DLBCL) cell lines in co-culture with Rituximab, and it shows considerable promise in both solid and hematologic malignancy research, positioning it as a potential candidate for immuno-oncology applications. |
Synonyms | CC-95251, CC95251, BMS-986351, BMS986351 |
Cas No. | 2543693-10-1 |
Color | Transparent |
Appearance | Liquid |
Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.